Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 11:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 967 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endothelium Clear all
Completed Phase 2 Interventional Results available

Thromboxane Receptor Antagonist to Improve Endothelial Function

NCT03962855
View directory record Official record
Conditions
Cardiovascular Diseases, Vascular Dilation
Interventions
Ifetroban Sodium, Placebo
Drug
Lead sponsor
Jeffrey Rade
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jun 26, 2026, 11:03 PM EDT
Terminated Phase 4 Interventional Results available

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

NCT04707625
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept Ophthalmic
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

NCT01522950
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, atenolol, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Jun 26, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

NCT07024693
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Fuchs
Interventions
DT-168
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NightWare and Cardiovascular Health in Adults With PTSD

NCT05365607
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Cardiovascular Diseases, Autonomic Dysfunction, Vascular Stiffness, Nightmare, Endothelial Dysfunction
Interventions
NightWare, Sham NightWare
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Vitamin D Statues on Endothelial Function

NCT01049048
View directory record Official record
Conditions
Cardiovascular Diseases, Vitamin D Deficiency
Interventions
Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 65 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Juice Plus+® Supplementation on Endothelial Function in Overweight Men

NCT01533987
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Juice Plus
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Jun 26, 2026, 11:03 PM EDT
Terminated No phase listed Observational

CEC/EPC and Cardiovascular Risk in Renal Transplant Recipients

NCT00365833
View directory record Official record
Conditions
Transplantation, Kidney, Cardiovascular Abnormalities, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Jun 26, 2026, 11:03 PM EDT
Terminated Not applicable Interventional

Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure

NCT02783716
View directory record Official record
Conditions
Heart Failure
Interventions
Subcutaneous adipose tissue collection, Peripheral arterial tonometry (PAT)
Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

An Extension to Study MD7108240

NCT00733304
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Inflammation and Vascular Function in Atherosclerosis

NCT00760019
View directory record Official record
Conditions
Atherosclerosis
Interventions
salsalate, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Jun 26, 2026, 11:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions
BNT323, BNT327
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 11:03 PM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04611152
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

NCT02370784
View directory record Official record
Conditions
Scleroderma
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vascular and Metabolic Consequences of Adopting a Westernized Lifestyle

NCT03785470
View directory record Official record
Conditions
Vascular Diseases
Interventions
Fructose and physical inactivity
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 2 Interventional

Tart Cherry, Metabolic Syndrome, and Cardiovascular Risk

NCT02154100
View directory record Official record
Conditions
Metabolic Syndrome, Cardiovascular Diseases, Diabetes
Interventions
Tart Cherry, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
20 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Pressure Lowering Effects of Grape Juice

NCT00302809
View directory record Official record
Conditions
Hypertension
Interventions
Concord Grape Juice
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
21 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2009 · Synced Jun 26, 2026, 11:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Complement and Cardiovascular Risk in Adolescents

NCT02821104
View directory record Official record
Conditions
Cardiovascular Disease, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
12 Years to 18 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

NCT01004406
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jun 26, 2026, 11:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents

NCT00272233
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Jun 26, 2026, 11:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microgravity Effects on Co-cultured Vascular Cells Types

NCT03144492
View directory record Official record
Conditions
Microgravity Exposed Endothelial Cells
Interventions
Blood volume collected specifically for this study
Biological
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

NCT00496587
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Capecitabine, Gemcitabine, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease

NCT00445978
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Sapropterin Dihydrochloride
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Savannah, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Jun 26, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Soybean Based Diets and CVD Risk Factors

NCT00175097
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Diet: soybeans and products made thereof, Diet: soybean flour and products made thereof, Diet: soybean milk, Diet: Animal protein based diet
Other
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Jun 26, 2026, 11:03 PM EDT